Indication
As monotherapy for the maintenance treatment of adult patients with
advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Medicine details
- Medicine name:
- rucaparib (Rubraca)
- SMC ID:
- SMC2799
- Pharmaceutical company
- pharmaand GmbH (pharma&)
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 30 June 2025